GS-6615 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ischemic Heart Disease
Conditions
Ischemic Heart Disease
Trial Timeline
May 1, 2013 → Nov 1, 2013
NCT ID
NCT01847391About GS-6615 + Placebo
GS-6615 + Placebo is a phase 1 stage product being developed by Gilead Sciences for Ischemic Heart Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01847391. Target conditions include Ischemic Heart Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02377336 | Phase 2 | Withdrawn |
| NCT01847391 | Phase 1 | Completed |
Competing Products
20 competing products in Ischemic Heart Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin, Clopidogrel | Yuhan | Pre-clinical | 23 |
| DS-1040b + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| DS-1040b + Aspirin | Daiichi Sankyo | Phase 1 | 33 |
| DS1040b + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Pharmacological intensification based on olmesartan | Daiichi Sankyo | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| YM872 (zonampanel), t-PA (alteplase) | Astellas Pharma | Phase 2 | 52 |
| Regadenoson | Astellas Pharma | Approved | 85 |
| ASP2246 | Astellas Pharma | Phase 1/2 | 41 |
| Gadolinium + Adenosine | Astellas Pharma | Phase 2/3 | 65 |
| XY03-EA + XY03-EA Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Redasemtide + Placebo | Shionogi | Phase 2 | 52 |
| Statin | Shionogi | Approved | 85 |
| fospropofol + propofol | Eisai | Phase 2 | 52 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| SB623 Implant (2.5M) + SB623 Implant (5.0M) | Sumitomo Pharma | Phase 2 | 52 |
| Mesenchymal stem cell + Placebo | Rohto Pharmaceutical | Phase 2 | 52 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 52 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Repatha | Amgen | Approved | 84 |